Cargando…

Degarelix and its therapeutic potential in the treatment of prostate cancer

Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of patients with prostate cancer in whom hormonal therapy is indicated. Two phase II trials and one phase III have been published as full papers in the literature. In the dose-finding phase II studies an initial dose o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doehn, Christian, Sommerauer, Martin, Jocham, Dieter
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685243/ https://www.ncbi.nlm.nih.gov/pubmed/19503784

Ejemplares similares

Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
por: Rick, Ferenc G, et al.
Publicado: (2013)

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer
por: Tokiwa, Suguru, et al.
Publicado: (2017)

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

Grundlagen der systemischen Therapie
por: Schuler, Martin, et al.
Publicado: (2009)

Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
por: Ong, Shawn Y., et al.
Publicado: (2015)

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
por: Madhu, Basetti, et al.
Publicado: (2016)

Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
por: Hosseini, Seyed Alireza, et al.
Publicado: (2016)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
por: Sun, Yinghao, et al.
Publicado: (2020)

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
por: Roshani, Hossain, et al.
Publicado: (2021)

Effects of Docetaxel plus Degarelix on Quality of Life and Vascular Endothelial Growth Factor in Patients with Prostate Cancer
por: Li, Weiping, et al.
Publicado: (2022)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Investigation of the GnRH antagonist degarelix isomerization in biological matrices
por: Ferrazzano, Lucia, et al.
Publicado: (2023)

Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study
por: Palumbo, Carlotta, et al.
Publicado: (2021)

In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
por: Sakai, Monica, et al.
Publicado: (2015)

Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study
por: You, Dalsan, et al.
Publicado: (2015)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
por: Sciarra, Alessandro, et al.
Publicado: (2016)

Mistaken administration of a repeat loading dose of Degarelix leading to acute psychosis
por: Hamdoon, Musaab, et al.
Publicado: (2021)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer: Erratum
Publicado: (2016)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry
por: Geiges, Götz, et al.
Publicado: (2015)

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study
por: Ozono, Seiichiro, et al.
Publicado: (2017)

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
por: Tosco, Lorenzo, et al.
Publicado: (2018)

The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats
por: Jayusman, Putri Ayu, et al.
Publicado: (2018)

Grundlagen der systemischen Therapie
por: Doehn, C., et al.
Publicado: (2007)

Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study
por: Gez, Eliahu, et al.
Publicado: (2013)

Inhibitory effects of long-term repeated treatments of a sustainable GnRH antagonist, degarelix acetate, on caprine testicular functions
por: KAWATE, Noritoshi, et al.
Publicado: (2020)

Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers
por: Mbese, Zintle, et al.
Publicado: (2019)

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men
por: Olsson, Håkan, et al.
Publicado: (2017)

Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015
por: Bok, Robert A
Publicado: (2008)

Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety
por: Merola, David, et al.
Publicado: (2022)

Resilienz - lohnt die Beschäftigung?
por: Jocham, Dieter
Publicado: (2020)

The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer
por: Singh, Kanika, et al.
Publicado: (2021)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(−/−) mice
por: Knutsson, Anki, et al.
Publicado: (2016)

Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication
por: Gonnissen, Annelies, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_06lfc3c0j9l82v99iumdj3c592